Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug ABBV-547 enters first human safety trial

NCT ID NCT07232004

Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-stage study tests a single dose of ABBV-547 in healthy adults to check its safety, how the body processes it, and any side effects. About 121 participants in the US and Japan will receive either the drug or a placebo. The study has two parts with different dosing groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ABBV-547
What could go wrong
This is a very early Phase 1 trial in healthy volunteers, so it cannot show whether ABBV-547 works for any disease. The main goal is safety, not effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 121 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). * Part 1: BMI is \>= 18.0 to \<= 29.9 kg/m\^2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * Part 2: must have discontinued use of phototherapy (e.g., UVA or UVB) at least 2 weeks prior to the baseline visit (Day 1) and PUVA phototherapy at least 4 weeks prior to the baseline visit (Day 1). Exclusion Criteria: * History of any clinically significant sensitivity or allergy to any medication or food. * Part 2: uses any herbal supplements within the 2-week period prior to study treatment administration. * Part 2: received any biologics including investigational agents within 2.5 half-lives prior to Baseline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteer

Contacts and locations

Locations

  • Acpru /Id# 278638

    Grayslake, Illinois, 60030, United States

  • Advanced Clinical Research Institute - Tampa /ID# 279342

    Tampa, Florida, 33607, United States

  • Austin Institute for Clinical Research - Pflugerville /ID# 279387

    Pflugerville, Texas, 78660, United States

  • CenExel ACT- Anaheim Clinical Trials /ID# 279612

    Anaheim, California, 92801, United States

  • Center for Clinical Studies - Houston - Binz Street /ID# 279419

    Houston, Texas, 77004, United States

  • Dermatology Research Associates - Los Angeles /ID# 279383

    Los Angeles, California, 90045, United States

  • Dermatology Trial Associates /ID# 279984

    Bryant, Arkansas, 72022, United States

  • Equity Medical, LLC - Bronx /ID# 279808

    The Bronx, New York, 10455, United States

  • Fukuoka University Hospital /ID# 279530

    Fukuoka, 814-0180, Japan

  • Health Concepts /ID# 279529

    Rapid City, South Dakota, 57702, United States

  • Integrative Skin Science and Research - Location 2 /ID# 279386

    Sacramento, California, 95815, United States

  • MediSearch Clinical Trials /ID# 279416

    Saint Joseph, Missouri, 64506, United States

  • MetroBoston Clinical Partners /ID# 279992

    Boston, Massachusetts, 02135, United States

  • Minnesota Clinical Study Center /ID# 279987

    New Brighton, Minnesota, 55112, United States

  • Oregon Dermatology and Research Center /ID# 279391

    Portland, Oregon, 97210, United States

  • Skin Care Research Boca Raton /ID# 279988

    Boca Raton, Florida, 33486-2269, United States

  • Skin Specialists /ID# 279531

    Omaha, Nebraska, 68144, United States

  • The Skin Center Dermatology Group /ID# 279983

    New City, New York, 10956-7153, United States

  • Total Dermatology /ID# 279798

    Birmingham, Alabama, 35203-4024, United States

  • Trueblue Clinical Research - Tampa /ID# 281757

    Tampa, Florida, 33609, United States

  • University Dermatology & Vein Clinic - Darien /ID# 279986

    Darien, Illinois, 60561, United States

  • University of the Ryukyus Hospital /ID# 279918

    Ginowan-shi, Okinawa, 901-2725, Japan

  • Wellness Clinical Research - Miami Lakes /ID# 279803

    Miami Lakes, Florida, 33016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.